Liquidia Corp Files 8-K Report
Ticker: LQDA · Form: 8-K · Filed: Aug 19, 2024
Sentiment: neutral
Topics: sec-filing, financials
TL;DR
Liquidia Corp filed an 8-K on Aug 19, 2024, mostly for financial docs & other events.
AI Summary
On August 19, 2024, Liquidia Corporation filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events. No specific financial figures or significant corporate actions were detailed in the provided excerpt.
Why It Matters
This filing indicates that Liquidia Corporation is providing updated financial information and potentially disclosing other material events to the SEC, which is important for investors to monitor company activities.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently increases risk.
Key Players & Entities
- Liquidia Corporation (company) — Registrant
- August 19, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Morrisville, North Carolina (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Liquidia Corporation?
The filing is primarily for 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on August 19, 2024.
What is Liquidia Corporation's state of incorporation?
Liquidia Corporation is incorporated in Delaware.
Where are Liquidia Corporation's principal executive offices located?
The principal executive offices are located at 419 Davis Drive, Suite 100, Morrisville, North Carolina 27560.
What is the SEC file number for Liquidia Corporation?
The SEC file number for Liquidia Corporation is 001-39724.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-08-19 07:00:32
Filing Documents
- tm2421912d2_8k.htm (8-K) — 25KB
- tm2421912d2_ex99-1.htm (EX-99.1) — 18KB
- 0001104659-24-090676.txt ( ) — 219KB
- lqda-20240819.xsd (EX-101.SCH) — 3KB
- lqda-20240819_lab.xml (EX-101.LAB) — 33KB
- lqda-20240819_pre.xml (EX-101.PRE) — 22KB
- tm2421912d2_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On August 19, 2024, the Company issued a press release announcing that the U.S. Food and Drug Administration (i) granted tentative approval of YUTREPIA (treprostinil) inhalation powder for patients with pulmonary arterial hypertension ("PAH") and pulmonary hypertension associated with interstitial lung disease ("PH-ILD"), and (ii) simultaneously determined that Tyvaso DPI, approved on May 23, 2022, qualifies for a three-year new dosage form exclusivity for the chronic use of dry powder formulations of treprostinil for the approved indications. As a result, final approval of YUTREPIA for PAH and PH-ILD is delayed until after expiry of the three-year regulatory exclusivity for Tyvaso DPI on May 23, 2025. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference into this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 99.1 Press Release of Liquidia Corporation, dated August 19, 2024. 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. August 19, 2024 Liquidia Corporation By: /s/ Michael Kaseta Name: Michael Kaseta Title: Chief Financial Officer and Chief Operating Officer